The question many venture investors were asking themselves throughout 2009 seems to be, "is it safe to come out yet?" And that cautious approach to investing embraced by many VCs has translated into a significant dip in Series As. Still, START-UP has identified a baker's dozen to keep an eye on in 2010 and beyond. (See Exhibit 1.)
There were 60 new Series A investments in biopharma firms in 2009, down sharply from 2008 and 2007, which each...






